Tofacitinib versus methotrexate in rheumatoid arthritis: Patient-reported outcomes from the randomised phase III ORAL Start trial

RMD Open

Volumn 2, Issue 2, 2016, Pages

  Strand, Vibeke ^a   Lee, Eun Bong ^b   Fleischmann, Roy ^c   Alten, Rieke E ^d   Koncz, Tamas ^e   Zwillich, Samuel H ^e   Gruben, David ^e   Wilkinson, Bethanie ^e   Krishnaswami, Sriram ^e   Wallenstein, Gene ^e  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Seoul National University College of Medicine   (South Korea)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85015985399     PISSN: None     EISSN: 20565933     Source Type: Journal    
DOI: 10.1136/rmdopen-2016-000308     Document Type: Article

References (52)

1. Kosinski M, Kujawski SC, Martin R, et al. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. Am J Manag Care 2002;8:231-40.
2. Strand V, Singh JA. Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs 2010;70:121-45.
3. Khan NA, Spencer HJ, Abda E, et al. Determinants of discordance in patients' and physicians' rating of rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken) 2012;64:206-14.
4. Bartlett SJ, Hewlett S, Bingham CO III, et al. Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus. Ann Rheum Dis 2012;71:1855-60.
5. Desthieux C, Hermet A, Granger B, et al. Patient-physician discordance in global assessment in rheumatoid arthritis: a systematic literature review with metaanalysis. Arthritis Care Res (Hoboken) 2016; doi: 10.1002/acr.22902. [Epub ahead of print 5 Apr 2016].
6. van Tuyl LH, Hewlett S, Sadlonova M, et al. The patient perspective on remission in rheumatoid arthritis: 'You've got limits, but you're back to being you again'. Ann Rheum Dis 2015;74:1004-10.
7. Kirwan JR, Hewlett SE, Heiberg T, et al. Incorporating the patient perspective into outcome assessment in rheumatoid arthritis - progress at OMERACT 7. J Rheumatol 2005;32:2250-6.
8. van Tuyl LH, Sadlonova M, Davis B, et al. Remission in rheumatoid arthritis: working toward incorporation of the patient perspective at OMERACT 12. J Rheumatol 2016;43:203-7.
9. Fleischmann R, Strand V, Wilkinson B, et al. Relationship between clinical and patient-reported outcomes in a phase 3 trial of tofacitinib or MTX in MTX-naïve patients with rheumatoid arthritis. RMD Open 2016;2:e000232.
10. Strand V, Kavanaugh A, Kivitz A, et al. Long-term radiographic and patient-reported outcomes based on clinical disease activity index responses with tofacitinib at 6 months. Ann Rheum Dis 2016;75(Supp 2):243.
11. Strand V, Kavanaugh A, Kivitz A, et al. Long-term radiographic and patient-reported outcomes based on Clinical Disease Activity Index responses with tofacitinib at 6 months. Arthritis Rheumatol 2015;67(S10):Abstr 1633.
12. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36:729-40.
13. Gossec L, Dougados M, Rincheval N, et al. Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. Ann Rheum Dis 2009;68:1680-5.
14. Kirwan JR, Tugwell PS. Overview of the patient perspective at OMERACT 10 - conceptualizing methods for developing patient-reported outcomes. J Rheumatol 2011;38:1699-701.
15. Strand V, Boers M, Idzerda L, et al. It's good to feel better but it's better to feel good and even better to feel good as soon as possible for as long as possible. Response criteria and the importance of change at OMERACT 10. J Rheumatol 2011;38:1720-7.
16. Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 2011;186:4234-43.
17. Meyer DM, Jesson MI, Li X, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 2010;7:41.
18. Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013;381:451-60.
19. Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012;367:495-507.
20. Kremer J, Li ZG, Hall S, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 2013;159:253-61.
21. Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014;370:2377-86.
22. van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 2013;65:559-70.
23. van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012;367:508-19.
24. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
25. Wells G, Li T, Maxwell L, et al. Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. Ann Rheum Dis 2008;67:260-5.
26. Wells GA, Li T, Kirwan JR, et al. Assessing quality of sleep in patients with rheumatoid arthritis. J Rheumatol 2009;36:2077-86.
27. Strand V, Scott DL, Emery P, et al. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. J Rheumatol 2005;32:590-601.
28. Hays RD, Stewart AL. Sleep measures. In: Stewart AL, Ware JE Jr, eds. Measuring functioning and well being. Durham (NC): Duke University Press, 1992:235-9.
29. Christensen PM, Kristiansen IS. Number-needed-to-treat (NNT) - needs treatment with care. Basic Clin Pharmacol Toxicol 2006;99:12-6.
30. Burmester G, van der Heijde D, Strand V, et al. Effects of tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis receiving stable dose methotrexate: results of two Phase 3 studies. Arthritis Rheum 2012;64(Suppl 10):549.
31. Strand V, van der Heijde D, Zerbini CAF, et al. Oral Scan effects of the oral JAK inhibitor tofacitinib in combination with methotrexate on patient reported outcomes in a 24-month phase 3 trial of active rheumatoid arthritis. Arthritis Rheum 2013;65:S996, Abstract No. 2334 (abstract).
32. Strand V, Kanik K, Connell CA, et al. The effects of the oral JAK inhibitor CP-690,550 on patient reported outcomes in a phase 3 study of active rheumatoid arthritis. Ann Rheum Dis 2011;70:88.
33. Strand V, Kremer J, Li ZG, et al. Tofacitinib (CP-690,550) in combination with traditional disease-modifying anti-rheumatic drugs: patient-reported outcomes from a Phase 3 study in patients with active rheumatoid arthritis and an inadequate response to disease-modifying anti-rheumatic drugs. Arthritis Rheum 2011;63:S1032-3.
34. van Vollenhoven RF, Wallenstein G, Lee EB, et al. Effects of tofacitinib (CP-690,550), an oral Janus kinase inhibitor, or adalimumab on patient reported outcomes in a phase 3 study of active rheumatoid arthritis. Ann Rheum Dis 2012;71:206.
35. Genovese MC, Han C, Keystone EC, et al. Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study. J Rheumatol 2012;39:1185-91.
36. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
37. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
38. Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000;39:655-65.
39. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96.
40. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999;159:2542-50.
41. Strand V, Tugwell P, Bombardier C, et al. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 1999;42:1870-8.
42. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-43.
43. van der Heijde D, Klareskog L, Singh A, et al. Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial. Ann Rheum Dis 2006;65:328-34.
44. Kekow J, Moots RJ, Emery P, et al. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. Ann Rheum Dis 2010;69:222-5.
45. Emery P, Fleischmann R, van der Heijde D, et al. The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum 2011;63:1200-10.
46. Strand V, Rentz AM, Cifaldi MA, et al. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study. J Rheumatol 2012;39:63-72.
47. Strand V, Balbir-Gurman A, Pavelka K, et al. Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years. Rheumatology (Oxford) 2006;45:1505-13.
48. Emery P, Kosinski M, Li T, et al. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. J Rheumatol 2006;33:681-9.
49. Russell AS, Wallenstein GV, Li T, et al. Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. Ann Rheum Dis 2007;66:189-94.
50. Emery P, Fleischmann RM, Strusberg I, et al. Efficacy and safety of subcutaneous golimumab in methotrexate-naive patients with rheumatoid arthritis: five-year results of a randomized clinical trial. Arthritis Care Res (Hoboken) 2016;68:744-52.
51. Ware JE, Kosinski M, Dewey JE. How to score version two of the SF-36 health survey. Lincoln (RI): QualityMetric, Incorporated, 2000.
52. Strand V, Crawford B, Singh J, et al. Use of "spydergrams" to present and interpret SF-36 health-related quality of life data across rheumatic diseases. Ann Rheum Dis 2009;68:1800-4.